BioCentury | Feb 20, 2012
Company News

Karolinska Development cancer news

...cancer. The subsidiary will hold projects from portfolio companies Akinion Pharmaceuticals AB (Solna, Sweden) and GliGene AB...
...CD117 ) kinase inhibitor, is in Phase I/II testing to treat acute myelogenous leukemia (AML). GliGene...
BioCentury | Feb 20, 2012
Financial News

GliGene completes venture financing

...Date completed: 2/14/12 Type: Venture financing Raised: SEK6.8 million ($1 million) Investor: Karolinska Development Note: GliGene...
BioCentury | Feb 15, 2012
Financial News

GliGene debuts to focus on hedgehog pathway

...Newco GliGene AB (Solna, Sweden) raised SEK6.8 million ($1 million) from the KDev Oncology AB subsidiary of...
...SEK6.8 million ($1 million) from the KDev Oncology AB subsidiary of Karolinksa Development AB (SSE:KDEV). GliGene...
Items per page:
1 - 3 of 3
BioCentury | Feb 20, 2012
Company News

Karolinska Development cancer news

...cancer. The subsidiary will hold projects from portfolio companies Akinion Pharmaceuticals AB (Solna, Sweden) and GliGene AB...
...CD117 ) kinase inhibitor, is in Phase I/II testing to treat acute myelogenous leukemia (AML). GliGene...
BioCentury | Feb 20, 2012
Financial News

GliGene completes venture financing

...Date completed: 2/14/12 Type: Venture financing Raised: SEK6.8 million ($1 million) Investor: Karolinska Development Note: GliGene...
BioCentury | Feb 15, 2012
Financial News

GliGene debuts to focus on hedgehog pathway

...Newco GliGene AB (Solna, Sweden) raised SEK6.8 million ($1 million) from the KDev Oncology AB subsidiary of...
...SEK6.8 million ($1 million) from the KDev Oncology AB subsidiary of Karolinksa Development AB (SSE:KDEV). GliGene...
Items per page:
1 - 3 of 3